Clinical Results for Bladder Cancer Treated by Radiotherapy Without Concurrent Standard Chemotherapy.
To evaluate clinical outcomes of three-dimensional conformal radiotherapy (3D-CRT) alone in patients with bladder cancer who were unfit for concurrent standard chemotherapy. Between January 2007 and May 2016, 34 patients (20 men, 14 women) aged 65-97 years (median=83) with bladder cancer cT1-4bN0-1M1 were treated with conformal whole-bladder radiotherapy with fractions of 1.8-3 Gy up to a total dose of 40-50 Gy. Median survival was 10 months (range=1-99); 1-year and 3-year survival was 51.4% and 34.3%, respectively. Radiation dose >50 Gy was associated with improved survival. Three-year local control (LC) rate was 58.8%. On multivariate analysis, only radiation dose showed a significant association with LC. Our results demonstrated the safety and feasibility of radiotherapy in patients with bladder cancer unfit for concurrent standard chemotherapy. A higher radiation dose may confer superior LC and overall survival (OS) without complications.